Phase III Rinvoq Win in Crohn’s; Meat After CRC Dx? Kidney Disease and Cirrhosis

Another phase III study of upadacitinib (Rinvoq) induction in moderate to severe Crohn’s disease showed significantly improved rates of clinical remission and endoscopic response with the JAK inhibitor versus placebo among individuals who failed on conventional or biologic therapies, drugmaker AbbVie said.

Meanwhile, Janssen announced that a phase IIb trial of its IL-23 blocker guselkumab (Tremfya) in moderate to severe ulcerative colitis met its primary endpoint, with improved clinical remission rates versus placebo in patients with inadequate response to conventional therapies.

Eating red meat or processed meat after being diagnosed with colon cancer did not impact the time to recurrence or mortality. (JAMA Network Open)

Acute kidney disease developed in a third of patients hospitalized with cirrhosis. (Journal of Hepatology)

Mortality risk was attenuated by post-transplant statin use among patients with non-alcoholic steatohepatitis receiving a liver transplant. (Clinical Gastroenterology and Hepatology)

British dancer Amy Dowden had to be carried off stage after experiencing a Crohn’s disease flare-up during a tour performance. (Yahoo! News)

Higher induction and maintenance doses of adalimumab (Humira) was no better than a standard-dose regimen for clinical remission among patients with ulcerative colitis. (Gastroenterology)

A high-risk score on the TissueCypher assay independently predicted disease progression in Barrett’s esophagus patients. (Clinical Gastroenterology and Hepatology)

Please enable JavaScript to view the comments powered by Disqus.